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Background
Heart failure (HF) is frequently associated with dysregula-
tion of nitric oxide-mediated vascular tone. In HF patients
with left ventricular systolic dysfunction (LVSD), right
ventricular (RV) performance is an important determi-
nant of exercise capacity and prognosis. Abnormal regula-
tion of pulmonary vascular tone in these patients can lead
to an increase in RV afterload and diminished function at
rest and with exercise. The increased pulmonary vasomo-
tor tone in HF patients is responsive to nitric oxide (NO),
as administration of inhaled NO to patients with LVSD
reduces pulmonary vascular resistance (PVR) and
increases cardiac index (CI). As these beneficial effects of
inhaled NO persist only briefly after cessation of its
administration technically challenging to administercon-
tinuously to ambulatory patients, the hydrolysis of its sec-
ond messenger in vascular smooth muscle cells, cGMP, is
an alternative target for pharmacologic augmentation
through inhibition of phosphodiesterases (PDEs) respon-
sible for its catabolism. Selective inhibition of Type 5
PDE, the predominant PDE isoform responsible for
hydrolysis of cGMP in the lungs has been shown to lower
resting PVR and pulmonary capillary wedge pressure
(PCWP) and increase CI without causing systemichypo-
tension in LVSD patients
Methods and results
Thirteen patients with New York Heart Association class
III HF underwent assessment of right heart hemodynam-
ics, gas exchange, and first-pass radionuclide ventriculog-
raphy at rest and with cycle ergometry before and 60
minutes after administration of 50 mg of the oral PDE5
inhibitor sildenafil. Sildenafil reduced resting pulmonary
arterial pressure, systemic vascular resistance (SVR), and
PVR, and increased resting and exercise CI (P < 0.05 for
all) without altering mean arterial pressure, heart rate, or
PCWP. Sildenafil reduced exercise pulmonary arterial
pressure, PVR, and PVR/SVR ratio (Figure 1), which indi-
cate a selective pulmonary vasodilator effect with exercise.
Peak  increased (15 ± 9%) and ventilatory response
to CO2 output (VE/  slope) decreased (16 ± 5%) after
sildenafil treatment. Improvements in right heart hemo-
dynamics and exercise capacity were confined to patients
with secondary pulmonary hypertension (rest pulmonary
arterial pressure > 25 mm Hg).
Conclusion
The present study shows that in patients with systolic HF,
PDE5 inhibition with sildenafil improves peak 
reduces VE/  slope, and acts as a selective pulmonary
vasodilator during rest and exercise in patients with HF
and pulmonary hypertension The results of a recently
completed placebo-controlled study of chronic PDE5
inhibitor administration to HF patients with LVSD will be
discussed.
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Effect of sildenafil on the ratio of PVR to SVRFigure 1
Effect of sildenafil on the ratio of PVR to SVR. *P < 0.05 for 
comparisons between baseline and sildenafil. #P < 0.05 for 
between-group comparison of patients in the +PH and -PH 
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